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ABSTRACT 
Background:  
Chagas cardiomyopathy, caused by Trypanosoma cruzi infection, continues to be a neglected illness, 
and has a major impact on global health. The parasite undergoes several stages of morphological and 
biochemical changes during its life cycle, and utilizes an elaborated antioxidant network to overcome 
the oxidants barrier and establish infection in vector and mammalian hosts. Trypanothione synthetase 
(TryS) catalyzes the biosynthesis of glutathione-spermidine adduct trypanothione (T(SH)2) that is the 
principal intracellular thiol-redox metabolite in trypanosomatids.  
Methods and Results:  
We utilized genetic overexpression (TryShi) and pharmacological inhibition approaches to examine the 
role of TryS in T. cruzi proliferation, tolerance to oxidative stress and resistance to anti-protozoal 
drugs. Our data showed the expression and activity of TryS was increased in all morphological stages 
of TryShi (vs. control) parasites. In comparison to controls, the TryShi epimastigotes (insect stage) 
recorded shorter doubling time, and both epimastigotes and infective trypomastigotes of TryShi 
exhibited 36-71% higher resistance to H2O2 (50-1000 M) and heavy metal (1-500 M) toxicity. 
Treatment with TryS inhibitors (5-30 M) abolished the proliferation and survival advantages against 
H2O2 pressure in a dose-dependent manner in both TryS
hi and control parasites. Further, epimastigote 
and trypomastigote forms of TryShi (vs. control) T. cruzi tolerated higher doses of benznidazole and 
nifurtimox, the drugs currently administered for acute Chagas disease treatment.  
Conclusions:  
TryS is essential for proliferation and survival of T. cruzi under normal and oxidant stress conditions, 
and provides an advantage to the parasite to develop resistance against currently used anti-
trypanosomal drugs. TryS indispensability has been chemically validated with inhibitors that may be 
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INTRODUCTION 
Chagas cardiomyopathy, caused by a hemoflagellate protozoan Trypanosoma cruzi (T. cruzi or Tc), is 
a major health concern in Latin America and is an emerging infectious disease in the United States, 
Europe, Japan, and other countries [1]. The World Health Organization estimates that ~6-7 million 
people are infected worldwide, and ~10000 deaths per year are caused by this illness [2]. Indeed, the 
global health impact of T. cruzi infection and Chagas disease might be underestimated due to a lack 
of access to health system and inaccurate diagnosis in the endemic regions. The majority of 
individuals infected with T. cruzi control the acute parasitemia and remain clinically asymptomatic for 
the rest of their life. However, 30-40% of the infected individuals develop clinical symptoms that 
progress from cardiac hypertrophic remodeling (wall thickening) to dilated cardiomyopathy and 
ultimately result in cardiac arrest and death. Up to 10% of the patients may also develop digestive, 
neurological or mixed alterations.  
 
From the beginning of 1970s, two drugs, benznidazole (BZ) and to a lesser extent nifurtimox 
(NFX), are administered for the treatment of acute T. cruzi infection [3]. However, these drugs are well 
tolerated by children only, and even then exhibit varying efficacy against different parasite isolates 
belonging to discrete typing units (DTU) I-VI. Limited-to-no-efficacy of BZ and NFX is observed in 
chronically infected adult patients, and currently recommended dosages of BZ and NFX produce 
adverse reactions including abdominal pain, nausea, vomiting, rash, decreased appetite and 
headache in adults, resulting in discontinuation of treatment [4,5]. Adjuvant therapies that can 
decrease the efficacious dosages of BZ and NFX against T. cruzi infection will improve the tolerance 
and completion of anti-protozoal treatment. 
 
 Trypanothione synthetase (TryS) is a trypanosomatid-specific enzyme that catalyzes the two-
step synthesis of trypanothione (T(SH)2; N
1,N8-bis(glutathionyl)spermidine), from two molecules of 
glutathione (GSH; L-γ-Glu-Cys-Gly) and a spermidine core along with ATP consumption [6]. The N-
terminal domain of TryS possesses weak amidase activity and can hydrolyze T(SH)2. The T(SH)2, 
together with its associated enzyme trypanothione reductase (TR), can carry out many of the 
antioxidant and metabolic functions of the glutathione / glutathione reductase and thioredoxin / 
thioredoxin reductase systems in other organisms [7]. TryS is shown to be essential for the survival of 
T. brucei and Leishmania species [8,9]. Nevertheless, the role of TryS in T. cruzi biology is not 
delineated.  
 
In this study, we aimed to investigate the role of TryS in various life cycle stages of T. cruzi. 
For this, we developed genetically-modified TryS-overexpressing parasites (referred as TryShi) and 
repressed TryS activity with small enzyme inhibitors [10]. We evaluated the growth and survival of 
epimastigote (insect, replicative) and trypomastigote (infective) forms of TryShi and control parasites in 
the absence and presence of oxidative stress and TryS inhibitors. We also determined the effect of 
TryS overexpression and TryS inhibition on the efficacy of anti-protozoal drugs (NFX and BZ) against 
T. cruzi. We discuss the biological significance of TryS in T. cruzi development, and the 
pharmacological potential that selective inhibition of TryS offers in a single or combined therapeutic 
approach with drugs in clinical use. 
MATERIALS AND METHODS 
Parasites, plasmids, and transfection 
T. cruzi SylvioX10/4 strain (ATCC 50823) was maintained and propagated as epimastigote 
axenic culture in liver infusion-tryptose medium (LIT) supplemented with heat-inactivated, 10% fetal 
bovine serum (FBS). To obtain metacyclic trypomastigotes, epimastigotes were pelleted by 
centrifugation, re-suspended (5 x 108 cell/ml) in Triatomine Artificial Urine (TAU) medium (190 mM 
NaCl, 17 mM KCl, 2 mM CaCl2, 8 mM phosphate buffer, 2 mM MgCl2, pH 6.8) and incubated at 28°C 
for 3 h. Thereafter, parasites were transferred to TAU3AAG medium (TAU supplemented with 0.035% 
sodium bicarbonate, 10 mM L-proline, 50 mM sodium glutamate, 2 mM sodium L-aspartate and 
10 mM glucose) and incubated at 28°C for 72-96 h [11]. The mouse myoblast cell line C2C12 was 
purchased from the American Type Culture Collection and maintained in complete RPMI 1640 
medium. The metacyclic trypomastigotes were used to infect C2C12 cells, and culture derived 
trypomastigotes were maintained and propagated by continuous in vitro passage in C2C12 cells.  
 
For metacyclogenesis assay, epimastigotes in exponential growth were synchronized by 
incubating in culture media without FBS for 24 h and then changed to LIT supplemented with 10% 
triatomine gut homogenate [12] at 28°C. The number of metacyclic and epimastigote forms were 
recorded on alternative days for 10 days by light microscopy. The difference between parasites 
stages was established according to its form and movement. Results are expressed as percentage of 
differentiated parasites. 
 
The pTREX plasmid is designed to allow integration of the gene of interest in the ribosomal 
locus of T. cruzi [13]. To construct pTREX.TryS, forward and reverse oligonucleotides were designed 
using the GenBank AF311782.1 sequence to amplify full-length T. cruzi TryS gene with EcoRI and 
HindIII restriction sites for directional cloning. Total DNA was purified from 1 x 107 epimastigotes by 
phenol/chloroform extraction/ethanol precipitation method. Total DNA (100 ng) was used as template 
with TryS-specific oligonucleotides under standard PCR conditions performed on a Verity thermal 
cycler (Thermo Fisher Scientific, Waltham MA). The PCR product was cloned at the EcoRI/HindIII 
restriction sites in the pTREX expression vector. The pTREX.TryS plasmid was transformed 
into Escherichia coli DH5α competent cells, grown in LB Broth containing 100 μg/ml ampicillin, and 
purified with the Qiagen Plasmid Maxi Kit (#12162, Chatsworth, CA) according to the manufacturer's 
specifications. The recombinant plasmid clones were confirmed by restriction analysis and 
sequencing at the Cerela-CONICET facility (Tucumán, Argentina).  
 
For transfection, T. cruzi epimastigotes (1.5 x 108 per ml) in exponential growth phase were 
suspended in HBS solution (21 mM HEPES, 137 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4, 6 mM 
glucose, pH 7), and transfected with 20 µg of pTREX or pTREX.TryS plasmids by electroporation (2 
pulses of 1500 V, 25 µF) by using a BTX ECM 630 electroporator (MA, USA). The transfectants were 
selected in LIT complete medium with 300 µg/ml G418 sulfate (Corning, Corning NY) during 30 days, 
and then cloned by seeding in Difco blood (Usmaru) agar plates [14] supplemented with 300 µg/ml 
G418. Colonies were recovered after 30 days. 
 
To confirm genomic integration of pTREX-TryS, total DNA was isolated from clonal populations 
of wild type (WT), and pTREX- or pTREX.TryS-transfected epimastigotes (1x107 each), as above. 
Total DNA (100 ng) was subjected to standard PCR reaction with oligonucleotides complementary to 
the neomycin resistance gene.  A second set of oligonucleotides (T7-F and RIB-R) was used to check 
integration of the recombinant plasmid at the ribosomal locus in T. cruzi [15]. All oligonucleotides used 
in this study are listed in Supplemental S1 Table. 
 
TcTryS antisera 
The TryS protein sequence was analyzed by Kolaskar & Tongaonkar algorithm available at the 
ExPASy platform of the Swiss Institute of Bioinformatics (Lausanne, Switzerland), and the N-terminal 
peptide sequence (LQSLAVPFGCVQGY) predicted to exhibit maximum antigenicity was selected. 
The TryS peptide was synthetized at GenScript (Piscataway, NJ, USA) and conjugated to bovine 
serum albumin (BSA) by glutaraldehyde method. Polyclonal sera against TryS was raised by 
inoculating a rabbit by intradermal injection with 400 µg of BSA-conjugated TryS peptide in Freund´s 
complete adjuvant followed by two booster doses of 200 µg of TryS peptide with incomplete adjuvant 
at 30 days and 50 days after the first immunization. The serum was collected 15 days after the last 
immunization. To absorb the resulting anti-TryS antibodies, serum (5 ml) was incubated (1 h at room 
temperature followed by 12 h at 4oC) with 800 µg of recombinant TryS peptide coated on to 
nitrocellulose membrane. The antigen-bound antibody was eluted in 0.1 M glycine-HCl buffer (pH 
2.7), and neutralized with 1/10th volume of 2 M Tris-HCl, pH 8.0. 
  
Western blotting 
T. cruzi epimastigotes and trypomastigotes (3×107 parasites) were frozen overnight and 
homogenized in 100 µl lysis buffer (50 mM HEPES, 200 mM NaCl, and 1% NP-40, pH 7.4) containing 
a protease inhibitor cocktail. The parasite lysates (60 µg protein per well) were resolved on 10% 
polyacrylamide gel under reducing conditions, and transferred to Immobilon-P PVDF membrane 
(Millipore, Burlington MA). The membranes were blocked with 5% non-fat dry milk in 50 mM Tris pH 
7.0, 150 mM NaCl (TBS) for 1 h, washed thrice with TBS - 0.05% Tween 20 (TBST), and then 
incubated for 2 h with affinity-purified anti-TryS (1:200-dilution in TBST) or anti-GAPDH (kindly 
provided by Dr. C. Labriola, 1:1500 dilution) antisera. Membranes were washed with TBST and TBS, 
and incubated for 1 h with horseradish peroxidase-conjugated anti-rabbit secondary antibody (Sigma–
Aldrich, St. Louis, MO, 1:5000 dilution). The signal was developed and visualized by using an 
enhanced chemiluminescent detection reagent and hyperfilms (GE Healthcare Life Sciences, 
Pittsburgh, MA). 
 
Indirect immunofluorescence assay 
Epimastigotes were fixed with 4% paraformaldehyde in phosphate buffered saline (PBS), spotted on 
to poly-L-lysine-treated glass slides, and permeabilized with 0.1% Triton-X 100 in PBS. Slides were 
washed with PBS, and incubated at room temperature for 2 h with anti-TryS antisera (1:200 dilutions 
in TBST). After washing with PBS thrice, slides were incubated for 1 h with Alexa fluor 488-conjugated 
goat anti-rabbit secondary antibody (Thermo Fisher Scientific, 1:2000 dilution) and DNA was stained 
with DAPI. Slides were mounted in 70% glycerol, and examined with an Axio Imager 2 fluorescence 
microscope (Zeiss, San Diego, CA).  
  
Trypanothione synthetase activity 
The TryS activity was determined by using the malachite green reagent that measures the 
amount of inorganic phosphate released from ATP during catalysis [16]. Briefly, 50-µl reaction buffer 
(50 mM HEPES pH 8.0, 5 mM MgCl2, 1 mM DTT) containing 0.5 mM GSH, 10 mM spermidine, and 
1.5 mM ATP substrates was added to 96-well plates. The reagent was freshly prepared by mixing 0.5 
mM aqueous solution of malachite green (M6880, Sigma), 0.034 M ammonium molybdate in 4 M HCl, 
and 2% Tween 20 (3.0: 1.0: 0.6, v/v/v). Parasite homogenates were prepared by using 1.5-5x107 total 
cells. The reaction was initiated by adding epimastigote or trypomasatigote homogenates to the wells, 
and after 15 min incubation at 37°C, reaction was stopped with 200 µl of malachite green reagent. 
The colorimetric signal was allowed to develop for 30 min, and the change in absorbance was 
recorded at 650 nm on a Thermo Electron Multiskan Ascent Microplate Reader (Woonsocket, RI). 
Total proteins were measured by Bradford colorimetric assay (Bio-Rad). All reactions were tested in 
triplicate and the enzymatic activity was expressed as mU per mg protein. One unit (U) of activity is 
defined as the amount of enzyme that catalyzes the hydrolysis of 1 mol of ATP per minute under the 
conditions specified in each case. 
 
Trypanothione (T(SH)2) and glutathione (GSH) level 
Epimastigotes and trypomastigotes (pTREX- and pTREX.TryS-transfected) were resuspended 
in 4% (w/v) trichloroacetic acid (1 x 107 per 50 l) and incubated at 4 °C for 10 min. The lysates were 
centrifuged at 21,000 x g for 30 min at 4°C, and supernatants were then lyophilized, and resuspended 
in 30 µl of Milli-Q water to start enzymatic T(SH)2 determination. Samples (5 µl) were mixed in a 1:10 
ratio with reaction buffer (400 µM NADPH, 5 nM recombinant trypanothione reductase, 100 mM Tris-
HCl pH 7.5, 2 mM EDTA, 1 mM DTNB). T(SH)2-dependent DTNB reduction was measured in kinetic 
mode at 405 nm. GSH content was determined by a kinetic method, as described previously [17]. 
 
Growth curve, doubling time, and trypanocidal effect of TryS small molecule inhibitors 
For growth curves, non-clonal and clonal populations of pTREX- and pTREX.TryS-transfected 
epimastigotes were synchronized by incubating them in LIT medium without FBS for 48 h. 
Epimastigotes were seeded in 24-well plates (5x105 parasites/well in 1 ml complete LIT medium), and 
parasite number was quantified daily for 12 days by using a Neubauer chamber and light microscope 
equipped with 40X objective. The growth velocity and doubling time were calculated by the 
Exponential growth equation tool in GraphPad Prism 5 (La Jolla CA, USA). 
 
To confirm the doubling time, synchronized epimastigotes (5x106 per sample) were incubated 
in 1 ml PBS with 5 µM CellTrace CFSE (cat# C34554, Thermo Fisher Scientific) for 20 min, washed 
thrice, resuspended in 1 ml complete LIT media, and incubated again at 28°C for 3 days. Then, 
epimastigotes were centrifuged at 3000 RPM for 5 min, and incubated with Fixable Viability Dye 
eFluor 780 (1:1000 dilution in PBS, Invitrogen) at 4°C for 30 min. Thereafter, parasites were washed 
with PBS, and fixed with 4% formaldehyde for 20 min. Samples were visualized on a LSRII Fortessa 
Cell Analyzer, acquiring 100,000 events in a live cell gate, and further analysis was performed by 
using the FlowJo software (version 7.6.5, Tree-Star, San Carlo, CA).  
 
The TryS chemical inhibitors, KuOrb39 and KuOrb54 (S1 Figure), were synthesized as 
described by Orban et al [10] and are referred as 3d and 3h. Synchronized, clonal parasite cultures 
(pTREX- and pTREX.TryS transfectants) were seeded in 96-well flat-bottom cell culture plates, and 
KuOrb39 or KuOrb54 (0, 5, 10, or 30 µM) added. Epimastigotes (1x104/well/100 µl) were incubated at 
28oC for 24 h and trypomastigotes (2.5x105/well/100 µl) were incubated at 37°C / 5% CO2 for 6 h. The 
growth rate of epimastigotes and survival of trypomastigotes was monitored by quantifying the motile 
parasites by light microscopy.  
  
Resistance to reactive oxygen species (ROS) and anti-parasitic drugs 
For this, wild type (WT), pTREX- and pTREX.TryS transfectants were seeded in 96-well flat 
bottom cell culture plates as above. Parasites were incubated in triplicate with H2O2 (50-1000 µM), 
cadmium acetate (1-500 µM), nifurtimox (NFX, 1-400 µM), or benznidazole (BZ, 5-500 μM). In some 
experiments, parasites were co-incubated with 10-30 µM KuOrb54 or KuOrb39 to examine the effect 
of TryS inhibition on parasite resistance to H2O2 and anti-parasitic drugs. In all experiments, 
epimastigotes (1x104/well/100 µl complete LIT medium) were incubated at 28oC for 24 h and 
trypomastigotes (2.5x105/well/100 µl RPMI containing 10% FBS) were incubated at 37°C / 5% CO2 for 
6 h, and viable (motile) parasites were counted by light microscopy.  
 
Data analysis 
All data were analyzed by using GraphPad Prism 5 statistical package (La Jolla, CA). Data 
were acquired in at least two independent experiments performed on different days (triplicate 
observations per experiment), and expressed as mean value SEM. Data were analyzed by using a 
Student t  test and  One-way analysis of variance (ANOVA), and p values < 0.05 were considered 
significant. The drug activities were calculated by sigmoidal regression analysis (dose-response – 
inhibition model), and expressed as the concentration needed to inhibit epimastigote growth by 50% 
or to obtain a 50% mortality of non-replicative trypomastigotes (IC50). IC50 values are plotted as mean 




Transfection, overexpression, and activity of TryS in T. cruzi  
As a first step towards the study of TryS associated functions in the context of T. cruzi biology, 
we generated parasites that constitutively overexpress this enzyme. The insertion of the TryS-
encoding sequence in the pTREX vector was confirmed by restriction analysis and sequencing of the 
TryS open reading frame. T. cruzi SylvioX10 strain belonging to TcI DTU was transfected with 
pTREX.TryS and control (empty pTREX) plasmids and transfectants were selected with G418. We 
confirmed the insertion of pTREX.TryS in the parasite’s genome by PCR amplification of the 320 bp 
fragment encoding the neomycin gene selection marker with Neo-F and Neo-R oligonucleotides, and 
a 900 bp DNA fragment encompassing sequences of pTREX vector and the 18S ribosomal locus of 
the parasite genome by using the T7-F and RIB-R oligonucleotides (Fig.1A). The PCR amplification of 
these fragments in the transgenic but not in the WT parasites demonstrated that the pTREX ( TryS) 
was stably integrated into the ribosomal locus of T. cruzi (Fig.1B&1C). The transfectants were cloned 
and all studies from this point onward were conducted in clonal populations of the transgenic cell 
lines.  
 
Next, we evaluated the expression and activity of TryS in the transfectants. Western blotting 
showed that expression of TryS (74.5 kDa) was increased by >4-fold and >2.5-fold in epimastigote 
and trypomastigote stages, respectively, of T. cruzi clones transfected with pTREX.TryS (referred as 
TryShi) when compared to the content in control transfectants (referred as pTREX) (Fig.2A&2B).  No 
differences in GAPDH levels were noted in controls and TryShi parasites. Immunofluorescence 
staining with TryS antisera showed normal distribution of TryS in cytoplasm with some punctated 
dispersion pattern in all transfectants. The TryShi (vs. control) transfectants exhibited a substantial 
increase in cytoplasmic TryS level (Fig.2C, compare panel b and panel d). The enzymatic activity of 
TryS was determined by an end-point assay based on reaction of the inorganic phosphate released 
during TryS catalysis with malachite green reagent. The overall levels of TryS specific enzymatic 
activity (SEA) and the trypanothione (T(SH)2 content (produced by TryS enzymatic activity) were 
higher in trypomastigote stage compared to epimastigote stage (Fig.3A&3B). The overexpression of 
TryS (TryShi) resulted in an increase in enzymatic activity in epimastigote and trypomastigote forms 
(2-fold and 1.7-fold, respectively), as compared to that noted in control pTREX parasites (Fig.3A, 
p<0.05). No significant differences were observed in intracellular T(SH)2 content at epimastigote stage 
of both studied clones (pTREX and TryShi). In comparison, T(SH)2 metabolite level was increased by 
2.3-fold in TryShi (vs. pTREX) trypomastigotes (Fig.3B, p<0.05). The content of GSH, a T(SH)2 
precursor, was higher in the epimastigotes when compared to trypomastigotes of both clones (TryShi 
and pTREX) (Fig.3C). In contrast, GSH contents in TryShi trypomastigotes were ~24% lower than that 
estimated in pTREX parasites, indicating its higher consumption for T(SH)2 synthesis. Together, the 
results presented in Fig.2 and Fig.3 suggest that epimastigote and trypomastigote stages of T. cruzi 
stably transfected with pTREX.TryS overexpress a functionally active form of TryS.  
 
Role of TryS in replication, differentiation and survival of T. cruzi 
In T. brucei, the T(SH)2-system provides reducing power to sustain ribonucleotide reductase 
activity [18], the enzyme responsible for deoxyribonucleotide synthesis, which are the building blocks 
of DNA. Thus, with the aim to analyze the effects of TryS on T. cruzi proliferation, we plotted growth 
curves of synchronized clonal cultures of TryShi and control epimastigote form in complete LIT 
medium. The TryShi epimastigotes exhibited a significant increase in replication than was observed for 
the pTREX-transfected controls (doubling time: 1.77 and 2.05 days, respectively, Fig.4A&4B), and this 
difference became particularly evident in the late-log phase of the growth curve. The uncloned TryShi 
epimastigotes also exhibited a significantly higher rate of replication than the pTREX control 
epimastigotes (doubling time: 1.58 and 1.83 days, respectively, S2 Figure) at five days after seeding. 
Parasite proliferation was also assessed by a flow cytometry approach relying on the fluorescence 
loss of CFSE label after cell division. Three days after CFSE pulse labeling, 93% and 78% of the 
TryShi and pTREX epimastigotes exhibited cell division, respectively (Fig.4C). In both groups, ~99% 
epimastigotes were live-stained and viable (Fig.4D).  
 
Metacyclogenesis, i.e., differentiation of epimastigotes to metacyclic, infective trypomastigote 
form in the insect gut, involves the up-regulation of antioxidant defense genes, such as TryS [19,20]. 
We, therefore, evaluated if the TryS overexpression confers differentiation advantage to the 
epimastigotes. For this, TryShi and pTREX epimastigotes were incubated in presence of triatomine gut 
homogenate, resembling the natural differentiation process, and the number of parasites exhibiting 
differentiated morphologies were recorded for 10 days. The TryShi epimastigotes displayed a higher 
differentiation capacity upon stimulus as they achieved a 53% of differentiated forms out of the total 
population, whereas only 15% of the pTREX-transfected epimastigotes achieved metacyclic 
differentiation during 10 days (S3 Figure). 
 
Further evidence of the role of TryS in replication and survival of epimastigote and infective 
trypomastigte forms, respectively, was obtained by incubating the transgenic clones with paullone-
derived TryS-specific inhibitors [10]. The TryS inhibitors affected the proliferation of TryShi and control 
epimastigotes in a dose-dependent manner, though KuOrb39 was more effective than KuOrb54 in 
impairing epimastigote growth (Fig.5A). The growth of TryShi and pTREX-transfected epimastigotes 
was decreased in presence of 30 µM KuOrb39 by 28% and 54%, respectively (p<0.05). Likewise, 
TryS inhibitors affected the survival of infective, non-replicative trypomastigote forms of TryShi and 
pTREX parasites in a dose-dependent manner; and in this case, KuOrb54 was found to be more 
effective. For instance, exposure to 10 µM and 30 µM KuOrb54 resulted in a relative cell death of 25% 
and 52%, respectively, for TryShi trypomastigotes and of 50% and 75%, respectively, for wild type 
trypomastigotes (Fig.5B). Together, the results presented in Fig.4, Fig.5, and S3 Figure suggest that 
a) TryS is an essential enzyme required for replication of epimastigotes and survival of insect and 
mammalian stages of T. cruzi; and b) increased expression of TryS favors a shorter doubling time of 
epimastigote forms as well as their increased differentiation to the infective metacyclic form of T. cruzi.  
 
TryS increases tolerance to oxidative stress in T. cruzi life cycle 
Because T(SH)2 can scavenge ROS or neutralize them via the T(SH)2-dependent antioxidant 
machinery of the parasite, we next examined the effect of TryS overexpression on T. cruzi’s ability to 
survive under oxidative stress conditions. H2O2 is known to be a ubiquitous reactive oxygen molecule 
produced by the insect as well as the mammalian host immune system [21–23]. We incubated the 
insect and infective forms of pTREX, and TryShi parasites with 50-1000 µM H2O2, and evaluated the 
percent inhibition of growth and survival. The TryShi (vs. control) epimastigotes exhibited a ~1.7-fold 
increase in H2O2 tolerance, evident by 50% growth inhibition of TryS
hi and pTREX epimastigotes at 
169.6 µM and 99.1 µM H2O2, respectively (Fig.6A&6B, p<0.05). To verify that the increased 
resistance to H2O2 occurred in a TryS-dependent manner, we incubated the epimastigotes with 100 
µM H2O2 (~IC50 for pTREX-transfectants) in the presence of TryS inhibitors. We observed no additive 
effects of 10 µM KuOrb39 on H2O2-dependent inhibition of TryS
hi and control epimastigotes’ growth. 
However, increasing KuOrb39 concentration to 30 µM abolished the protective effects against H2O2 
observed for TryShi (vs. control) epimastigotes (Fig.6C). The data on survival of trypomastigotes upon 
challenge with increasing oxidant doses are presented in Fig.6D-6F. As noted for the epimastigote 
stage, the TryShi (vs. pTREX) trypomastigotes exhibited a 1.4-fold increase in H2O2 tolerance, that 
was evident by IC50 values of 87.7 µM and 64.6 µM H2O2 for TryS
hi and pTREX trypomastigotes, 
respectively (Fig.6D&6E). Co-incubation with 10 µM KuOrb54 had a significant effect on H2O2-
dependent killing of pTREX trypomastigotes, which was more clearly noticed after co-incubation with 
30 µM of the inhibitor. In comparison, TryShi trypomastigotes exhibited significantly higher capacity to 
resist oxidative stress even in presence of KuOrb54 (Fig.6F).  
 
It is known that metals may lead to an increase in ROS level and exert toxicity against T. cruzi 
[24]. We, therefore, investigated the effects of cadmium as an alternative oxidative stressor. The 
TryShi epimastigotes exhibited a >6-fold increase in Cd2+ tolerance when compared to pTREX with 
IC50 values of 31.4 µM and 5.1 µM, respectively (S4 Figure). In summary, the results presented in 
Fig.6 and S4 Figure suggest that: a) despite the low endogenous expression, TryS contributes to 
H2O2 management in epimastigote form; b) TryS and other antioxidant enzymes are up-regulated in 
trypomastigote (vs. epimastigote) form that also appears to be more sensitive to oxidants; and c) TryS 
provides protection from oxidative stress in both epimastigote and trypomastigote forms of T. cruzi. 
Further, d) TryS displays a pivotal role in heavy metal detoxification via T(SH)2 in T. cruzi. We surmise 
that up-regulation of TryS can potentially increase parasites’ tolerance to oxidative stress in the vector 
as well as in the mammalian host. 
 
TryS increases T. cruzi resistance to anti-parasite drug therapies 
Nifurtimox (NFX) and benznidazole (BZ) are drugs of choice for the treatment of T. cruzi 
infection. NFX is a nitrofurane derivative, and it is believed to exert its biological activity through 
formation of a highly reactive and cytotoxic unsaturated open-chain nitrile [25] and, secondly, through 
thiol depletion [26]. To analyze the effect of TryS overexpression on parasite resistance to NFX, we 
incubated the pTREX and TryShi parasites with 1-400 µM NFX, and determined the inhibition 
percentage of proliferation of the replicative epimastigotes and survival of the non-replicative 
trypomastigotes. The TryShi epimastigotes showed >3-fold increase in NFX tolerance, with IC50 values 
of 5.93 µM and 1.84 µM for TryShi and pTREX epimastigotes, respectively (Fig.7A&7B, p<0.0001). 
Notably, the infective TryShi trypomastigotes showed a 7.5-fold higher resistance towards NFX than 
the pTREX cells. This was evidenced by IC50 values of 16.53 µM and 2.19 µM NFX for TryS
hi and 
pTREX trypomastigotes, respectively (Fig.7C&7D, p<0.0001). Independently of the genetic 
background, co-incubation with KuOrb54 significantly decreased trypomastigote resistance to NFX. 
Nonetheless, the effect of the TryS inhibitor was significantly less marked for TryShi than for pTREX 
trypomastigotes. This was evidenced by finding of 50%, 59% and 69% cell death of pTREX 
trypomastigotes; and 27%, 34%, and 55% cell death of TryShi trypomastigotes in the presence of 2.5 
µM NFX only, NFX plus 10 µM, and 30 µM KuOrb54, respectively (Fig.7E, all p<0.05).  
 
It has been already demonstrated that benznidazole, a nitroimidazole, has a pleiotropic effect 
by depleting low molecular mass thiols through the formation of adducts and thereby enhancing 
oxidative stress [27]. The TryShi epimastigotes showed >4.5-fold increase in BZ tolerance, with IC50 
value of 26.1 µM and 5.3 µM for TryShi and pTREX epimastigotes, respectively (Fig.8A&8B, 
p<0.0001).  Similar to the behavior against NFX, the TryShi trypomastigotes showed a 1.7-fold 
increase in BZ tolerance with IC50 values of 120.2 µM and 68.6 µM BZ for TryS
hi and pTREX 
trypomastigotes, respectively (Fig.8C&8D, p<0.0001). Furthermore, co-incubation with KuOrb54 
significantly enhanced the toxicity of BZ against trypomastigote form independently of the genetic 
background. This was evidenced by finding of 50%, 64%, and 86% cell death of pTREX 
trypomastigotes; and 31%, 48% and 74% death of TryShi trypomastigotes in the presence of 60 µM 
BZ only, BZ with 10 µM and 30 µM KuOrb54, respectively (Fig.8E, all p<0.05). Altogether, the results 
presented in Fig.7 & Fig.8 suggest that TryS confers NFX and BZ resistance to T. cruzi epimastigote 
and trypomastigote stages and that the paullone inhibitors offer potential as adjuvant therapy for 
enhancing nitroheterocyclic drug efficacy against T. cruzi. 
 
DISCUSSION  
Herein, we describe the generation of recombinant T. cruzi with genomic insertion of an extra 
copy of the TryS gene. The aim of this approach was to elucidate the role of TryS enzyme in the 
context of T. cruzi biology. The TryShi parasites, as compared to controls, exhibited increased levels 
of TryS protein in all stages of parasite development analyzed (Figures 1-3). The increased 
expression and activity of TryS was particularly evident in infective form when recombinant TryS led to 
increased T(SH)2 synthesis from spermidine and GSH substrates. The overexpression of TryS 
enhanced the replication and survival of T. cruzi under physiological conditions as well as in the 
presence of oxidative and heavy metal stress (Figures 4-6 and S4 Figure). Further, overexpression of 
TryS conferred an advantage to the parasite to develop resistance to currently used anti-
trypanosomal drugs and TryS small molecule inhibitors were efficacious in improving the efficacy of 
NFX and BZ against T. cruzi (Figure 7 and Figure 8). The important role of TryS in parasite 
proliferation, infectivity and resistance against oxidative stress have previously been shown in T. 
brucei [18,28] and L. infantum [29] that are related pathogenic trypanosomatids. To the best of our 
knowledge, this is the first study in which we have employed the genetic overexpression and small 
molecule inhibitors to demonstrate the biological significance of TryS in T. cruzi development, survival 
and resistance to oxidative stress and anti-parasite therapies. Our data allow us to propose that TryS 
small molecule inhibitors offer adjuvant therapy for lowering the efficacious dose of anti-parasite drugs 
in killing T. cruzi. 
 
The TryS enzyme produces T(SH)2 and the latter is maintained in its reduced state by the 
NADPH-dependent flavoenzyme trypanothione reductase (TR) [7]. T(SH)2 (reduced form) transfers 
electrons to the multipurpose thiol/disulfide oxidoreductase tryparedoxin (TXN). TXN plays a central 
role as biological catalyst, reducing a large diversity of molecular targets such as  different types of 
peroxidases and ribonucleotide reductase [30]. Metabolic flux studies performed in T. cruzi highlighted 
that TryS/T(SH)2, γ-glutamylcysteine synthetase, the first enzyme of the GSH biosynthetic pathway, 
and TXN are the rate-limiting steps in the antioxidant network of the parasite [31]. In the T. cruzi 
epimastigote form that replicates and undergoes metacyclogenesis in insects, trypanothione 
antioxidant network was not very active. This was evidenced by the finding of low expression of TryS 
(Figures2&3) and other proteins of the antioxidant network in epimastigote form of T. cruzi [20,32,33]. 
Further, the GSH level in epimastigotes was >2.5-fold higher than that observed in the infective stage 
(Fig.3C). Overexpression of TryS in epimastigotes was clearly insufficient to cause an increase in the 
T(SH)2 content. These findings suggest that either the attained level of enzyme was yet the rate 
limiting step or that additional component(s) of the system (i.e.  polyamine uptake) exert a higher 
metabolic control of the pathway. Regardless of the reasons for this metabolic output and the 
observed significance of GSH being the predominant low molecular weight thiol in epimastigotes 
(TryShi or pTREX), our results indicate that TryS/T(SH)2 supported growth, survival, and higher 
replication rate in TryShi (vs. control) epimastigotes, a phenotype that was abolished upon selective 
inhibition of the enzyme (Figure 4, Figure 5, and Figure 6). Such advantageous outcomes may be 
associated to the fact that the T(SH)2-system supported the synthesis of DNA precursors [18] and the 
replication of the parasite mitochondrial DNA [34,35]. Interestingly, the axenic epimastigotes displayed 
a marked increase in their proliferation rate during the late phase of the growth curve, when the 
culture milieu undergoes an important shift in the ratio of nutrients to metabolic products. Although 
with a lower efficiency than that occurring in the insect gut, this metabolic change triggers the 
differentiation of axenic epimastigotes into the highly infective and non-replicative metacyclic 
trypomastigotes [36,37]. It is, thus, tempting to speculate that up-regulation of TryS under in vivo 
conditions may be beneficial to achieve a larger amount of epimastigotes that may undergo 
metacyclogenesis and establish the infective inoculum. Indeed differentiation process seems to be 
enhanced in TryS-overexpressing parasites (S3 Figure) when compared to the wild type clone. One 
possible explanation could be related to the higher content of antioxidant defenses that could be 
somehow monitored by the parasite as a metacyclogenesis driving force.  
 
Trypomastigotes are released from host cells and swim in interstitial fluid and bloodstream 
until they invade a new cell, such as macrophages. Both the extracellular medium and the invasion of 
activated macrophages represent an oxidative challenge for trypomastigotes. This may explain the 
need for a higher content of TryS/T(SH)2 in this parasite stage. In agreement with this proposal and 
the almost absolute T(SH)2-dependency of the hydroperoxide metabolism of the parasite [38–40], 
overexpression of TryS in both epimastigotes and trypomastigotes conferred protection against H2O2, 
a physiological oxidant produced by macrophages as part of the host immune response. The slight, 
but significant (p<0.001, Figure 6D), difference observed between TryShi and pTREX trypomastigotes 
suggests that reactions downstream to T(SH)2 synthesis may limit the capacity of the system to 
neutralize or repair the damage caused by H2O2. In  this regard, it is important to recall that the 
reaction between T(SH)2 and TXN has been pointed to be the rate limiting step in the hydroperoxide 
metabolism of trypanosomatids [31,41]. 
Paullones are a group of 7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-ones that were initially 
described for their inhibitory activity against mammalian protein kinases, among other effects. Orban 
and co-workers developed novel N5 aryl-substituted derivatives of 3-chlorokenpaullone that displayed 
significant inhibitory activity against the recombinant TcTryS protein [10]. From this group of 
compounds, the on-target effect of KuOrb39 (referred as 3d in [10]) and KuOrb54 (referred as 3 h in 
[10]) was tested for the first time in T. cruzi in this study. Both compounds exerted a remarkable 
cytotoxic effect against both life stages of the parasite that were subject of our study. Specifically, IC50 
concentration of KuOrb54 (~10 μM) against T. cruzi parasite was similar to the levels needed to 
observe 50% inhibition of the recombinant enzyme [10]. The apparent higher sensitivity of 
trypomastigotes to the cytotoxic action of the paullones is likely explained by the fact that this stage is 
not replicative. In almost all assays, except for that conducted against epimastigotes at 30 μM 
compounds, the 4-hydroxy phenyl derivative KuOrb54 exhibited a higher cytotoxicity than the 3-chloro 
phenyl analogue KuOrb39. The observed plateau in anti-epimastigote activity of KuOrb54 when 
added at 30 μM may likely be due to an impaired uptake and/or bioavailability of this molecule. 
Another important finding is that KuOrb54 displayed potent anti-trypanosomal activity against a 
clinically relevant form of the parasite (trypomastigotes) at concentrations below (50% and 75% cell 
death at 10 μM and 30 μM, respectively) to that observed for the drug BZ (IC50 = 69 μM). Conversely, 
KuOrb54 was comparatively less active than the potent drug NFX (IC50 = 2 μM).  
 
As commented previously, the mechanism of action of both anti-protozoal drugs leads to 
depletion of low molecular weight thiols [26,27,42]. The involvement of trypanothione metabolism in 
neutralization of nitro-drugs has been demonstrated for different trypanosome species. In T. brucei, 
RNAi-mediated downregulation of TryS sensitized the parasite against the action of NFX [43]. In T. 
cruzi, treatment with buthionine sulfoximine, an inhibitor of γ-glutamylcysteine synthetase, enhanced 
the anti-trypanosomal activity of NFX and/or BZ in vitro and in vivo (unpublished observations). Here, 
we provide conclusive evidence for the direct implication of TryS/T(SH)2 in the management of BZ- 
and NFX-induced stress in T. cruzi. The role of TryS was particularly noticeable in NFX detoxification, 
as the IC50 value of NFX was estimated to be ~7.5-fold higher for TryS
hi parasites than that observed 
for pTREX trypomastigotes (Figure 7C). Importantly, chemical inhibition of TryS increased parasite 
sensitivity towards NFX and BZ (Figure 7E&8E), as noted by IC50 values for these drugs that were >2-
fold lower than those obtained in cells not exposed to paullones. Overall, these results suggest that 
TryS is a resistance gene for current anti-chagasic drugs, and lead us to speculate that its 
endogenous up-regulation – observed in some virulent parasite strains [33] – is, at least in part, 
associated to cases of drug failure.  
 
SUMMARY 
By employing reverse genetics and chemical inhibition approaches, we analyzed the 
importance of trypanothione synthetase in T. cruzi biology. TryS proved relevant for the proliferation of 
the insect stage (epimastigote) of the parasite under starvation conditions, which may favor 
metacyclogenesis to infective trypomastigotes form. The higher expression of TryS conferred to the 
parasite an advantage to deal with the oxidative stress produced by different sources (e.g. H2O2 and 
cadmium), in the replicative epimastigote as well as in the infective trypomastigotes forms of the 
parasite. Furthermore, T. cruzi overexpressing TryS tolerated higher dosages of anti-protozoal drugs, 
benznidazole and nifurtimox, suggesting that the protein may contribute to the drug failure cases. 
Specific TryS inhibitors proved beneficial in increasing parasite’s sensitivity to anti-parasitic drugs and 
should be considered in the design of new treatment strategies. 
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SUPPLEMENTARY DATA 
S1 Table: Oligonucleotides used in this study. Oligonucleotides 1 and 2 were designed for TryS 
amplification and directional cloning into the pTREX vector. Oligonucleotides 1-4 were used to confirm 
the sequence of TryS open reading frame in pTREX.TryS vector. Total DNA isolated from WT and 
transfectants (pTREX and pTREX.TryS) was used as template with Neo-F and Neo-R 
oligonucleotides for PCR amplification of neomycin-encoding gene (Neo in pTREX) and with T7-F and 
RIB-R oligonucleotides to amplify a DNA fragment encompassing sequence from pTREX and 18S 
ribosomal locus in T. cruzi genome.  
 
S1 Figure: Chemical structure of small molecule inhibitors of Trypanosoma cruzi 
trypanothione synthetase. The TryS inhibitors KuOrb39 and KuOrb54 are referred as 3c and 3d in 
Orban et al [10]. 
  
S2 Figure: Growth curve of non-clonal populations of TryS-overexpressing T. cruzi. (A) 
Epimastigotes were transfected with pTREX or pTREX.TryS (TryShi) plasmids, and incubated under 
G418 selection pressure for 30 days. Parasite cultures were seeded at 5 x 105 epimastigotes/ml 
complete LIT medium in 24 well plates, and parasite growth was monitored up to 12 days by light 
microscopy. The data are representative of three independent experiments (three determinations per 
sample per experiment), and plotted as mean value ± SEM. (B) The doubling times of TryShi and 
control epimastigote populations were calculated by using a GraphPad Prims 5 software. Rate 
constant k fitted for an exponential growth curve differed significantly between the two datasets (p < 
0.05). 
 
S3 Figure: TryS-overexpression favors metacyclogenesis. Epimastigotes of pTREX– and 
pTREX.TryS-transfected clones in exponential growth phase were synchronized by incubating in 
culture media without FBS for 24 h, and then were transferred to complete LIT medium supplemented 
with 10% triatomine gut homogenate. The differentiation of epimastigotes to metacyclic forms was 
recorded by light microscopy. The data are representative of ≥ 3 independent experiments (three 
determinations per sample per experiment) and plotted as mean value ± SEM (* and *** correspond to 
p < 0.05 and p < 0.001, respectively). 
 
S4 Figure: TryS overexpression confers cadmium tolerance. Clonal epimastigote cultures of 
TryShi and control T. cruzi were incubated for 48 h with 0-500 µM cadmium acetate. The viable, motile 
epimastigotes were visually quantitated by light microscopy. (A) IC50 concentration of cadmium that 
resulted in 50% inhibition of TryShi (vs. control) parasites. (B) Parasite growth inhibition curve fitted 
after incubation with increasing concentrations of cadmium acetate. All experiments were conducted 
thrice (three determinations per sample per experiment), and data are plotted as mean value ± SEM 
(*** p < 0.001).   
REFERENCES 
[1] G.A. Schmunis, Epidemiology of Chagas disease in non-endemic countries: the role of 
international migration, Mem. Inst. Oswaldo Cruz. 102 (2007) 75–85. doi:10.1590/S0074-
02762007005000093. 
[2] WHO | Chagas disease (American trypanosomiasis), (2017). 
http://www.who.int/mediacentre/factsheets/fs340/en/ (accessed April 15, 2018). 
[3] J.R. Coura, S.L. De Castro, A critical review on chagas disease chemotherapy, Mem. Inst. 
Oswaldo Cruz. 97 (2002) 3–24. doi:10.1590/S0074-02762002000100001. 
[4] L. Lauria-Pires, M.S. Braga, A.C. Vexenat, N. Nitz, A. Simões-Barbosa, D.L. Tinoco, A.R.L. 
Teixeira, Progressive chronic chagas heart disease ten years after treatment with anti-
Trypanosoma cruzi nitroderivatives, Am. J. Trop. Med. Hyg. 63 (2000) 111–118. 
[5] C.A. Morillo, J.A. Marin-Neto, A. Avezum, S. Sosa-Estani, A. Rassi, F. Rosas, E. Villena, R. 
Quiroz, R. Bonilla, C. Britto, F. Guhl, E. Velazquez, L. Bonilla, B. Meeks, P. Rao-Melacini, J. 
Pogue, A. Mattos, J. Lazdins, A. Rassi, S.J. Connolly, S. Yusuf, Randomized trial of 
benznidazole for chronic Chagas’ cardiomyopathy, N. Engl. J. Med. 373 (2015) 1295–1306. 
doi:10.1056/NEJMoa1507574. 
[6] S.L. Oza, E. Tetaud, M.R. Ariyanayagam, S.S. Warnon, A.H. Fairlamb, A Single Enzyme 
Catalyses Formation of Trypanothione from Glutathione and Spermidine in Trypanosoma cruzi, 
J. Biol. Chem. 277 (2002) 35853–35861. doi:10.1074/jbc.M204403200. 
[7] R.L. Krauth-Siegel, M.A. Comini, Redox control in trypanosomatids, parasitic protozoa with 
trypanothione-based thiol metabolism, Biochim. Biophys. Acta - Gen. Subj. 1780 (2008) 1236–
1248. doi:10.1016/J.BBAGEN.2008.03.006. 
[8] S. Wyllie, S.L. Oza, S. Patterson, D. Spinks, S. Thompson, A.H. Fairlamb, Dissecting the 
essentiality of the bifunctional trypanothione synthetase-amidase in Trypanosoma brucei using 
chemical and genetic methods, Mol. Microbiol. 74 (2009) 529–540. doi:10.1111/j.1365-
2958.2009.06761.x. 
[9] A.F. Sousa, A.G. Gomes-Alves, D. Benítez, M.A. Comini, L. Flohé, T. Jaeger, J. Passos, F. 
Stuhlmann, A.M. Tomás, H. Castro, Genetic and chemical analyses reveal that trypanothione 
synthetase but not glutathionylspermidine synthetase is essential for Leishmania infantum, 
Free Radic. Biol. Med. 73 (2014) 229–238. doi:10.1016/j.freeradbiomed.2014.05.007. 
[10] O.C.F. Orban, R.S. Korn, D. Benítez, A. Medeiros, L. Preu, N. Loaëc, L. Meijer, O. Koch, M.A. 
Comini, C. Kunick, 5-Substituted 3-chlorokenpaullone derivatives are potent inhibitors of 
Trypanosoma brucei bloodstream forms, Bioorganic Med. Chem. 24 (2016) 3790–3800. 
doi:10.1016/j.bmc.2016.06.023. 
[11] V.T. Contreras, T.C. Araujo-Jorge, M.C. Bonaldo, N. Thomaz, H.S. Barbosa, M.N. Meirelles, S. 
Goldenberg, Biological aspects of the Dm 28c clone of Trypanosoma cruzi after 
metacyclogenesis in chemically defined media, Mem. Inst. Oswaldo Cruz. 83 (1988) 123–133. 
doi:S0074-02761988000100016 [pii]. 
[12] E.L. Isola, E.M. Lammel, S.M. González Cappa, Trypanosoma cruzi: differentiation after 
interaction of epimastigotes and Triatoma infestans intestinal homogenate., Exp. Parasitol. 62 
(1986) 329–35. http://www.ncbi.nlm.nih.gov/pubmed/3023131 (accessed September 17, 2018). 
[13] M.P. Vazquez, M.J. Levin, Functional analysis of the intergenic regions of TcP2β gene loci 
allowed the construction of an improved Trypanosoma cruzi expression vector, Gene. 239 
(1999) 217–225. doi:10.1016/S0378-1119(99)00386-8. 
[14] D.B. Evans, D.  odfrey, S. Lanham, F. Lanotte,  enevi ve, Modabber, Handboo  on isolation, 
characterization and cryopreservation of Leishmania geneva: World Health Organization, 1989. 
http://www.who.int/iris/handle/10665/60795. 
[15] H.A. Lorenzi, M.P. Vazquez, M.J. Levin, Integration of expression vectors into the ribosomal 
locus of Trypanosoma cruzi, Gene. 310 (2003) 91–99. doi:10.1016/S0378-1119(03)00502-X. 
[16] C. Fusari, A.M. Demonte, C.M. Figueroa, M. Aleanzi, A.A. Iglesias, A colorimetric method for 
the assay of ADP-glucose pyrophosphorylase, Anal. Biochem. 352 (2006) 11–13. 
doi:10.1016/j.ab.2006.01.024. 
[17] D.G. Arias, V.E. Marquez, M.L. Chiribao, F.R. Gadelha, C. Robello, A.A. Iglesias, S.A. 
Guerrero, Redox metabolism in Trypanosoma cruzi: functional characterization of tryparedoxins 
revisited, Free Radic. Biol. Med. 63 (2013) 65–77. doi:10.1016/j.freeradbiomed.2013.04.036. 
[18] M. Dormeyer, N. Reckenfelderbäumer, H. Lüdemann, R.L. Krauth-Siegel, Trypanothione-
dependent synthesis of deoxyribonucleotides by Trypanosoma brucei ribonucleotide reductase, 
J. Biol. Chem. 276 (2001) 10602–10606. doi:10.1074/jbc.M010352200. 
[19] A. Parodi-Talice, V. Monteiro-Goes, N. Arrambide, A.R. Avila, R. Duran, A. Correa, B. 
Dallagiovanna, A. Cayota, M. Krieger, S. Goldenberg, C. Robello, Proteomic analysis of 
metacyclic trypomastigotes undergoing Trypanosoma cruzi metacyclogenesis., J. Mass 
Spectrom. 42 (2007) 1422–32. doi:10.1002/jms.1267. 
[20] J.A. Atwood, D.B. Weatherly, T.A. Minning, B. Bundy, C. Cavola, F.R. Opperdoes, R. Orlando, 
R.L. Tarleton, The Trypanosoma cruzi proteome, Science. 309 (2005) 473–6. 
doi:10.1126/science.1110289. 
[21] P. Azambuja, E.S. Garcia, P.J. Waniek, C.S. Vieira, M.B. Figueiredo, M.S. Gonzalez, C.B. 
Mello, D.P. Castro, N.A. Ratcliffe, Rhodnius prolixus: from physiology by Wigglesworth to 
recent studies of immune system modulation by Trypanosoma cruzi and Trypanosoma rangeli, 
J. Insect Physiol. (2016). doi:10.1016/j.jinsphys.2016.11.006. 
[22] F.A. Zumaya-Estrada, J. Martínez-Barnetche, A. Lavore, R. Rivera-Pomar, M.H. Rodríguez, 
Comparative genomics analysis of triatomines reveals common first line and inducible 
immunity-related genes and the absence of Imd canonical components among 
hemimetabolous arthropods, Parasit. Vectors. 11 (2018) 48. doi:10.1186/s13071-017-2561-2. 
[23] L. Piacenza, M. Alvarez, G. Peluffo, R. Radi, Fighting the oxidative assault: the Trypanosoma 
cruzi journey to infection, Curr Opin Microbiol. 12 (2009) 415–421. 
doi:10.1016/j.mib.2009.06.011. 
[24] L.P. de Carvalho, E.J.T. de Melo, Life and death of Trypanosoma cruzi in presence of metals, 
BioMetals. 30 (2017) 955–974. doi:10.1007/s10534-017-0064-4. 
[25] B.S. Hall, C. Bot, S.R. Wilkinson, Nifurtimox activation by trypanosomal type I nitroreductases 
generates cytotoxic nitrile metabolites, J. Biol. Chem. 286 (2011) 13088–13095. 
doi:10.1074/jbc.M111.230847. 
[26] M. Boiani, L. Piacenza, P. Hernández, L. Boiani, H. Cerecetto, M. González, A. Denicola, Mode 
of action of nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: is 
oxidative stress involved?, Biochem. Pharmacol. 79 (2010) 1736–45. 
doi:10.1016/j.bcp.2010.02.009. 
[27] A. Trochine, D.J. Creek, P. Faral-Tello, M.P. Barrett, C. Robello, Benznidazole 
biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics, PLoS 
Negl. Trop. Dis. 8 (2014). doi:10.1371/journal.pntd.0002844. 
[28] M.A. Comini, S.A. Guerrero, S. Haile, U. Menge, H. Lünsdorf, L. Flohé, Validation of 
Trypanosoma brucei trypanothione synthetase as drug target, Free Radic. Biol. Med. 36 (2004) 
1289–1302. doi:10.1016/j.freeradbiomed.2004.02.008. 
[29] R. Mukhopadhyay, S. Dey, N. Xut, D. Gaget, J. Lightbody, M. Ouellette, B.P. Rosen, 
Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania, 
Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 10383–10387. doi:10.1073/pnas.93.19.10383. 
[30] F. Irigoín, L. Cibils, M.A. Comini, S.R. Wilkinson, L. Flohé, R. Radi, Insights into the redox 
biology of Trypanosoma cruzi: Trypanothione metabolism and oxidant detoxification, Free 
Radic. Biol. Med. 45 (2008) 733–742. doi:10.1016/j.freeradbiomed.2008.05.028. 
[31] Z. González-Chávez, V. Olin-Sandoval, J.S. Rodíguez-Zavala, R. Moreno-Sánchez, E. 
Saavedra, Metabolic control analysis of the Trypanosoma cruzi peroxide detoxification pathway 
identifies tryparedoxin as a suitable drug target, Biochim. Biophys. Acta - Gen. Subj. 1850 
(2015) 263–273. doi:10.1016/j.bbagen.2014.10.029. 
[32] M.P. Zago, Y.M. Hosakote, S. jie Koo, M. Dhiman, M.D. Piñeyro, A. Parodi-Talice, M.A. 
Basombrio, C. Robello, N.J. Garg, TcI isolates of Trypanosoma cruzi exploit the antioxidant 
network for enhanced intracellular survival in macrophages and virulence in mice, Infect. 
Immun. 84 (2016) 1842–1856. doi:10.1128/IAI.00193-16. 
[33] L. Piacenza, M.P. Zago, G. Peluffo, M.N. Alvarez, M.A. Basombrio, R. Radi, Enzymes of the 
antioxidant network as novel determiners of Trypanosoma cruzi virulence, Int. J. Parasitol. 39 
(2009) 1455–1464. doi:10.1016/j.ijpara.2009.05.010. 
[34] I. Onn, N. Milman-shtepel, J. Shlomai, Redox potential regulates binding of universal minicircle 
sequence binding protein at the kinetoplast DNA replication origin, Eukaryot Cell. 3 (2004) 277–
287. doi:10.1128/EC.3.2.277. 
[35] R. Singh, B. Purkait, K. Abhishek, S. Saini, S. Das, S. Verma, A. Mandal, A.K. Ghosh, Y. 
Ansari, A. Kumar, A.H. Sardar, A. Kumar, P. Parrack, Universal minicircle sequence binding 
protein of Leishmania donovani regulates pathogenicity by controlling expression of 
cytochrome ‑ b, Cell Biosci. (2016) 1–17. doi:10.1186/s13578-016-0072-z. 
[36] A. Hamedi, L. Botelho, C. Britto, S.P. Fragoso, A.C.S. Umaki, S. Goldenberg, G. Bottu, D. 
Salmon, In vitro metacyclogenesis of Trypanosoma cruzi induced by starvation correlates with 
a transient adenylyl cyclase stimulation as well as with a constitutive upregulation of adenylyl 
cyclase expression, Mol. Biochem. Parasitol. 200 (2015) 9–18. 
doi:10.1016/j.molbiopara.2015.04.002. 
[37] R.C. Figueiredo, D.S. Rosa, M.J. Soares, Differentiation of Trypanosoma cruzi epimastigotes: 
metacyclogenesis and adhesion to substrate are triggered by nutritional stress., J. Parasitol. 86 
(2000) 1213–8. doi:10.1645/0022-3395(2000)086[1213:DOTCEM]2.0.CO;2. 
[38] E.G.S. Carnieri, S.N.J. Moreno, R. Docampo, Trypanothione-dependent peroxide metabolism 
in Trypanosoma cruzi different stages, Mol. Biochem. Parasitol. 61 (1993) 79–86. 
doi:10.1016/0166-6851(93)90160-Y. 
[39] L. Piacenza, G. Peluffo, M.N. Alvarez, A. Martínez, R. Radi, Trypanosoma cruzi antioxidant 
enzymes as virulence factors in Chagas disease, Antioxid. Redox Signal. 19 (2013) 723–734. 
doi:10.1089/ars.2012.4618. 
[40] J.K. Finzi, C.W.M. Chiavegatto, K.F. Corat, J.A. Lopez, O.G. Cabrera, A.A. Mielniczki-Pereira, 
W. Colli, M.J.M. Alves, F.R. Gadelha, Trypanosoma cruzi response to the oxidative stress 
generated by hydrogen peroxide, Mol. Biochem. Parasitol. 133 (2004) 37–43. 
doi:10.1016/j.molbiopara.2003.08.011. 
[41] M.A. Comini, R.L. Krauth-Siegel, L. Flohé, Depletion of the thioredoxin homologue tryparedoxin 
impairs antioxidative defence in African trypanosomes., Biochem. J. 402 (2007) 43–9. 
doi:10.1042/BJ20061341. 
[42] J.D. Maya, Y. Repetto, M. Agosin, J.M. Ojeda, R. Tellez, C. Gaule, A. Morello, Effects of 
Nifurtimox and benzonidazole upon glutathione and trypanothione content in epimastigote, 
tripomastigote and amastigote forms of Trypanosoma cruzi, Mol. Biochem. Parasitol. 86 (1997) 
101–106. 
[43] M.R. Ariyanayagam, S.L. Oza, M.L.S. Guther, A.H. Fairlamb, Phenotypic analysis of 
trypanothione synthetase knockdown in the African trypanosome, Biochem. J. 391 (2005) 425–
432. doi:10.1042/BJ20050911. 
 
Figure 1: Stable integration of pTREX.TryS expression vector in T. cruzi. (A) Scheme of 
pTREX.TryS and pTREX expression vectors integration into the ribosomal locus of T. cruzi genome. 
Full-length TryS coding sequence (1960 bp) was amplified by using the Tc SylvioX10/c4 DNA as 
template in a PCR reaction, and cloned downstream of HX1 intergenic region (HX1) at EcoRI/HindIII 
sites in pTREX plasmid. (B&C) Sylvio X10/c4 epimastigotes were electroporated with pTREX or 
pTREX.TryS plasmids and transfectants were selected in presence of G418. Representative PCR 
amplification of neomycin resistance gene (Neo, B) and T7 – ribosomal locus (C) in pTREX and 
pTREX.TryS (TryShi) transfectants are shown. Note that no amplification of pTREX-derived 
sequences was observed in wild-type (WT) parasites. 
Figure 2: TryS enzyme is over-expressed in pTREX.TryS-transfected T. cruzi. The pTREX and 
pTREX.TryS (TryShi) transfectants were cloned as described in Materials and Methods.  (A&B) 
Representative Western blot images are shown for the levels of TcTryS and TcGAPDH in clonal 
populations of epimastigote (A) and trypomastigotes (B) forms. Detection of GAPDH (housekeeping 
protein) was used as loading control. Ponceau staining of the gel is also shown as an evidence for 
equal loading of epimastigote lysates. (C) Shown are representative bright field (a&c) and 
fluorescence (b&d) images of pTREX-transfected (a&b) and pTREX.TryS-transfected (c&d) 
epimastigotes. For immunofluorescence, parasites were stained with anti-TryS antisera and Alexa-
488-conjugated secondary antibody (green) together with DAPI (blue, DNA marker). 
Figure 3: Recombinant TryS is produced as an active enzyme in epimastigote and 
trypomastigote forms of T. cruzi. Clonal epimastigote (Epi) and trypomastigote (Tryp) forms of 
pTREX- and pTREX.TryS-transfectants were expanded as described in Materials and Methods. Bar 
graphs present the (A) specific enzymatic activity (SEA) of TryS, (B) total trypanothione (T(SH)2) 
content by an enzymatic recycling method, and (C) content of total GSH. The data in bar graphs are 
representative of ≥ 2 independent experiments (three determinations per sample per experiment) and 
plotted as mean value ± SEM (* and *** correspond to p < 0.05 and p < 0.001, respectively, ns stands 
for non significant). 
Figure 4: Effect of TryS overexpression on parasite growth. (A) The growth of synchronized 
epimastigote cultures of pTREX and pTREX.TryS (TryShi) transfectants was monitored by cell 
counting under a light microscope. Data are representative of three independent experiments (three 
determinations per sample per experiment), and plotted as mean value ± SEM. (B) The doubling time 
of TryShi and control epimastigotes was calculated in GraphPad Prims 5. Rate constant k fitted for an 
exponential growth curve differed significantly between the two datasets (p < 0.05). (C) pTREX and 
TryShi clonal epimastigote populations were pulse labeled with CFSE and examined 3 days later by 
flow cytometry. The decline in CFSE fluorescence intensity corresponds to cell division. (D) A fixable 
viability dye was used to gate CFSE+ viable cells. For both pTREX and TryShi populations, 99% of the 
analyzed parasites were viable.  
Figure 5: Effect of TryS inhibitors on T. cruzi replication and viability. Clonal cultures of TryShi 
and control epimastigote and trypomastigote forms of T. cruzi were incubated in presence of varying 
concentrations of TryS inhibitors (0, 5, 10, and 30 µM of KuOrb39 or KuOrb54). (A) The percentage 
(%) of growth inhibition of epimastigotes at 24 h post-incubation was determined by counting live, 
motile parasites by light microscopy. (B) Live motile trypomastigotes were quantitated by light 
microscopy, and percentage (%) of cell death calculated at 6 h post-incubation. Data are 
representative of two independent experiments (three determinations per sample per experiment), 
and plotted as mean value ± SEM (* p < 0.05).   
Figure 6: Role of TryS in T. cruzi resistance to oxidative stress. T. cruzi transfectants, pTREX 
and pTREX.TryS (TryShi), were cloned and expanded as described in Materials and Methods. Cloned 
epimastigote (A-C) and trypomastigote (D-F) populations were incubated for 48 h and 6 h 
respectively, in presence of 0-1000 µM H2O2 and 0-30 µM of TryS inhibitors KuOrb39 or KuOrb54. 
(A&D) IC50 concentration of H2O2 that resulted in 50% inhibition of TryS
hi (vs. control) parasites. 
(B&E) Parasite growth or survival inhibition curves fitted after incubation with increasing H2O2 
concentrations. (C&F) Percentage (%) inhibition of growth or survival of TryShi (vs. control parasites) 
in presence of H2O2 at its ~IC50 value and varying concentrations of TryS antagonists. For all 
experiments, viable, motile parasites were visually quantitated by light microscopy. All experiments 
were conducted at least twice (three determinations per sample per experiment), and data are plotted 
as mean value ± SEM (* p < 0.05).   
Figure 7: TryS inhibition is detrimental to parasite resistance to nifurtimox. Clonal cultures of 
TryShi and control epimastigotes (A&B) and trypomastigotes (C-D) of T. cruzi were incubated for 48 h 
or 6 h respectively, with 0-400 µM nifurtimox (NFX) in presence or absence of KuOrb54 (10 µM or 30 
µM). (A&C) IC50 concentration of NFX that resulted in 50% inhibition of TryS
hi (vs. control) parasite 
forms. (B&D) Parasite growth or survival inhibition curves fitted after incubation with increasing 
concentrations of NFX. (E) Percentage (%) inhibition of trypomastigotes’ survival in presence of 2.5 
µM NFX (IC50 value) and KuOrb 54 (10 and 30 µM). All experiments were conducted twice (three 
determinations per sample per experiment), and data are plotted as mean value ± SEM (* p < 0.05).   
Figure 8: TryS inhibitors increase T. cruzi susceptibility to benznidazole. Clonal cultures of 
pTREX and TryShi epimastigote (A-B) and trypomastigote (C-D) forms of T. cruzi were incubated for 
48 h and 6 h respectively, with benznidazole (BZ, 0-500 µM) in presence or absence of KuOrb54 (10 
µM and 30 µM). (A&C) IC50 concentration of BZ that resulted in 50% inhibition of TryS
hi (vs. control) 
epimastigote and trypomastigote forms of T. cruzi. (B&D) Parasite growth or survival inhibition curves 
fitted after incubation with increasing concentrations of benznidazole. (E) Percentage (%) inhibition of 
TryShi (vs. control) trypomastigotes’ survival in presence of 60 µM BZ (IC50 value) and TryS antagonist 
KuOrb 54 (10 and 30 µM). All experiments were conducted twice (three determinations per sample 
per experiment), and data are plotted as mean value ± SEM (* p < 0.05).   
HIGHLIGHTS  
 Trypanothione synthetase (TryS) is an essential enzyme for T. cruzi. 
 TryS-overexpression confers higher replication rate to T. cruzi epimastigotes. 
 TryS provides protection against oxidative stress to different parasite stages. 
 TryS confers resistance to current treatment drugs, benznidazole and nifurtimox. 
 
 
 
 
 
 
 
 
 
